Three kinds of drug-eluting bead transarterial chemoembolisation for treating patients with unresectable non-small cell lung cancer

Figure 4 Survival follow-up. A: Progression-free survival was the highest in the oxaliplatin (OXA) group (median: 9.9 months, interquartile range (IQR): 2.5-13.4 months), followed by the gemcitabine (GEM) (median: 7.2 months, IQR: 2.0-9.2 months) and doxorubicin (DOX) (median: 6.8 months, IQR: 2.7-8.4 months) groups (P = 0.31, χ² = 2.363); B: The OXA group exhibited increased overall survival (median: 29.6 months, IQR: 4.6-18.5 months) compared with the GEM (median: 10.7 months, IQR: 3.1-11.2 months, P = 0.04, χ² = 4.357) and DOX (median: 10.2 months, IQR: 3.8-14.5 months) groups (P = 0.02, χ² = 5.875). DOX: Doxorubicin; OXA: Oxaliplatin; GEM: Gemcitabine.